# SUPN catalysts: Supernus, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/supn/catalysts

> Supernus, Inc. (SUPN) has 8 upcoming catalysts. The next is the spn-821 2400 mg topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Supernus, Inc. |
| Ticker | SUPN (Nasdaq) |
| SEC CIK | 1625297 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/supn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 6, 2020 | [Qelbree (viloxazine hydrochloride) complete response letter (CRL)](https://sec-api.dev/pdufa/viloxazine) | SUPN |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22211964_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| May 2023 | [OPVEE (nalmefene) FDA approval](https://sec-api.dev/pdufa/nalmefene) | SUPN |  | completed, approved | "OPVEE was approved by the FDA in May 2023 and launched in October 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000003/exhibit991q42024pressrelea.htm)) |
| Sep 2024 | [INDV-6001 trial start](https://sec-api.dev/pdufa/indv-6001) | SUPN |  | completed | "In September 2024, we initiated a multiple dose clinical Phase 2 Pharmacokinetic study (NCT06576843)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm)) |
| February 24, 2025 | [BRIXADI (buprenorphine) FDA approval](https://sec-api.dev/pdufa/buprenorphine) | SUPN | moderate to severe opioid use disorder | completed, approved | "On February 24, 2025, the FDA approved label changes for SUBLOCADE, including a rapid initiation protocol and alternative injection sites, which further improve the patient and physician experience and mark an advancement in the treatment of moderate to severe opioid use disorder (OUD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381dex991.htm)) |
| April 24, 2025 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Announces Results for the First Quarter Ended March 31, 2025; FY 2025 Guidance Unchanged" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381dex991.htm)) |
| July 31, 2025 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/d908304dex991.htm)) |
| October 30, 2025 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/d58033dex991.htm)) |
| February 26, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/d713689dex991.htm)) |
| April 30, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/d40828dex991.htm)) |
| August 3, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566dex991.htm)) |
| September 2026 | [Viloxazine extended-release capsules primary completion](https://sec-api.dev/pdufa/viloxazine-extended-release) | SUPN | Attention-Deficit/Hyperactivity Disorder | delayed | "NCT02736656 (Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02736656)) |
| Sep to Dec 2026 | [Viloxazine extended-release capsules topline data readout](https://sec-api.dev/pdufa/viloxazine-extended-release) | SUPN | Attention-Deficit/Hyperactivity Disorder | scheduled | "NCT02736656 (Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02736656)) |
| October 29, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm)) |
| Dec 2026 to Mar 2027 | [Spn-821 2400 mg topline data readout](https://sec-api.dev/pdufa/spn-821) | SUPN | Major Depressive Disorder (MDD) | scheduled | "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226661)) |
| December 2026 | [Spn-821 2400 mg primary completion](https://sec-api.dev/pdufa/spn-821) | SUPN | Major Depressive Disorder (MDD) | scheduled | "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226661)) |
| August 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT06798896 (RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798896)) |
| Aug to Nov 2027 | [SPN-817 topline data readout](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT06798896 (RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798896)) |
| Dec 2027 to Mar 2028 | [SPN-817 topline data readout](https://sec-api.dev/pdufa/spn-817) | SUPN | Epilepsy; Seizures, Epileptic | scheduled | "NCT05518578 (Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05518578)) |
| Dec 2027 to Mar 2028 | [SPN-817 topline data readout](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT07141329 (SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07141329)) |
| December 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Epilepsy; Seizures, Epileptic | scheduled | "NCT05518578 (Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05518578)) |
| December 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT07141329 (SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07141329)) |

## Drugs

- [BRIXADI (buprenorphine)](https://sec-api.dev/pdufa/buprenorphine): moderate to severe opioid use disorder
- [INDV-6001](https://sec-api.dev/pdufa/indv-6001): 
- [OPVEE (nalmefene)](https://sec-api.dev/pdufa/nalmefene): 
- [SPN-817](https://sec-api.dev/pdufa/spn-817): Epilepsy, Focal Onset Seizures
- [Spn-821 2400 mg](https://sec-api.dev/pdufa/spn-821): Major Depressive Disorder (MDD)
- [Qelbree (viloxazine hydrochloride)](https://sec-api.dev/pdufa/viloxazine): 
- [Viloxazine extended-release capsules](https://sec-api.dev/pdufa/viloxazine-extended-release): Attention-Deficit/Hyperactivity Disorder

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/supn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SUPN catalysts: Supernus, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/supn/catalysts

```bibtex
@misc{secapidev_companies_supn_catalysts_20261116,
  title        = {SUPN catalysts: Supernus, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/supn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_supn_catalysts_20261116","title":"SUPN catalysts: Supernus, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/supn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
